Mesothelin expression in ovarian cancer and its potential as targeted ovarian cancer immunotherapy

Global Congress on Tissue Engineering, Regenerative & Precision Medicine

December 1-2, 2016 | San Antonio, USA

Samir A. Farghaly

Cornell University, USA

Posters & Accepted Abstracts: J Tissue Sci Eng

Abstract :

Ovarian cancer is the fourth most common cause of cancer death in women. Most patients are diagnosed at stage III and IV, with resultant low relative-survival rates. The current treatments with conventional cytotoxic chemotherapy and novel surgical techniques have improved the oncologic outcome of this disease. However, recurrence is common. Current evidence suggests that the immune system and its ability to recognize and eliminate the microscopic disease is of significant importance in preventing recurrence. Immunotherapy for ovarian cancer is to balance the activation of the immune system against this cancer while preventing the potential for toxicity elicited by immune modulation. Mesothelin, a glycosylphosphatidylinositol (GPI) anchored cell surface protein, is a potential target for antibody-based ovarian cancer immunotherapy due to its high expression in ovarian cancer. Human monoclonal antibodies targeting mesothelin have been isolated by phage display technology and it provides opportunities for novel ovarian cancer immunotherapy. In addition, CRS-207 is live-attenuated Listeria monocytogenes (Lm), which has been genetically modified to be safe for human use while retaining its ability to stimulate an immune response against the protein mesothelin.

Biography :

Email: samirfarghaly@yahoo.com